![Dose-escalated Radiation Therapy With and Without Short-course Androgen Deprivation for Intermediate-risk Prostate Cancer | Anticancer Research Dose-escalated Radiation Therapy With and Without Short-course Androgen Deprivation for Intermediate-risk Prostate Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/34/8/4189/F1.large.jpg)
Dose-escalated Radiation Therapy With and Without Short-course Androgen Deprivation for Intermediate-risk Prostate Cancer | Anticancer Research
![The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR: Molecular Therapy The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR: Molecular Therapy](https://www.cell.com/cms/attachment/4076fa72-4571-40d7-ac60-b96e7f73dc1a/gr8_lrg.jpg)
The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR: Molecular Therapy
![Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation like CyberKnife Radiotherapy | MedStar Health Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation like CyberKnife Radiotherapy | MedStar Health](https://www.medstarhealth.org/-/media/project/mho/medstar/news-images/georgetown/mguh_cyberknife_newsroom_post.jpg?h=784&iar=0&w=1380&hash=81FA0B223186E1EB9E0E78367273BAF9)
Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation like CyberKnife Radiotherapy | MedStar Health
![Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial - The Lancet Oncology Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/fecc61fc-6781-4bed-aaf2-761274255384/gr1_lrg.jpg)
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial - The Lancet Oncology
![Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation | Georgetown University Medical Center | Georgetown University Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation | Georgetown University Medical Center | Georgetown University](https://gumc.georgetown.edu/wp-content/uploads/2019/02/GeorgetownLombardi-logo-780-390.jpg)
Large Study Reveals Long-Term Outcomes for Prostate Cancer Patients Treated with High Dose, Short Term Radiation | Georgetown University Medical Center | Georgetown University
![Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges | British Journal of Cancer Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01881-9/MediaObjects/41416_2022_1881_Fig1_HTML.png)